Skip to content Skip to footer
Subscribe Now
Takeda at AASLD 2024: Chinwe Ukomadu in a Riveting Dialogue Exchange with PharmaShots
VIEWPOINTS

Takeda at AASLD 2024: Chinwe Ukomadu in a Riveting Dialogue Exchange with PharmaShots

Shots:  AATD-associated liver disease is a progressive genetic disorder with no approved therapy, and liver transplantation remains the only option for patients with end-stage disease. Fazirsiran is an investigational RNAi therapy designed to treat AATD-associated liver disease by lowering the production of Z-AAT. PharmaShots welcomes Dr. Chinwe Ukomadu, Head of the Gastrointestinal and Inflammation Therapeutic…
May 5, 2025

Read more

VIEWPOINTS_Brian Ingram_2023
VIEWPOINTS

Brian Ingram, Director, Discovery & Translational Sciences at Metabolon Shares his Views on the Expansion of its Inflammation Portfolio

Shots:Brian briefed our readers about Metabolon’s inflammation portfolio expansion with the launch of new Targeted Panels studying cannabinoids, sphingolipids, and lipid mediators of inflammation including its Oxysterols Targeted PanelHe also talked about Endocannabinoids and Sphingolipids and how Metabolon targeted panels are used for their measurementsThe interview highlights how Metabolon’s mission to deliver…
July 6, 2023

Read more

VIEWPOINTS_Rui Avelar_2023
VIEWPOINTS

Rui Avelar, CMO and Head of R&D at Evolus Shares Insights from Interim P-II Data Results Evaluating an “Extra-Strength” Formulation of Jeuveau

Shots:Rui gave the details about the “extra-strength” formulation of Jeuveau. He highlighted the study design and results of the trial evaluating  Jeuveau. The data indicated that the “extra-strength” formulation of Jeuveau at 40U achieved a duration profile of 6 months or 26 weeksThe data was presented at the 2023 IMCAS World Congress in…
June 13, 2023

Read more

VIEWPOINTS_Eric Halioua_2023
VIEWPOINTS

Eric Halioua, President & CEO at PDC*line Pharma Shares Insights on the Results from P-I/II Trial with PDC*lung01

Shots:Eric shared the results from the first immunological results of its PDC-LUNG-101 P-I/II trial with PDC*lung01 which is the company’s cancer vaccine candidate for Non-Small Cell Lung CancerThe results were presented at ESMO-IO 2022 elaborating on the safety, tolerability, immunogenicity, and preliminary clinical activity of the drug candidateThe interview shows PDC*line’s vision…
June 1, 2023

Read more

VIEWPOINTS_Monica Mann_2023
VIEWPOINTS

Monica Mann, VP, of Medical Affairs for Global MS and Pipeline at Biogen Shares Insights on New Data on MS Therapies and Digital Health Research

Shots:Monica spoke about the new data from its multiple sclerosis therapies portfolio presented at the 38th ECTRIMS meetingThe highlights from the presentation were the safety and efficacy results of Vumerity, patient-reported outcomes from the treatment with Tysabri, and posters highlighting advances in digital health initiativesThe interview shows how Biogen develops, and delivers…
May 31, 2023

Read more

Michael G. Chez and Greg Grunberg Share Insights from “The Care Giver” Series Based on Epilepsy
VIEWPOINTS

Michael G. Chez and Greg Grunberg Share Insights from “The Care Giver” Series Based on Epilepsy

Shots:Dr.Chez talked about the challenges faced in epilepsy diagnosis and its various treatment optionsGreg spoke about the new online series sponsored by Jazz Pharmaceuticals and how it benefits people with EpilepsyThe interview summarizes the vital role of caregivers in the lives of those living with epilepsySmriti: Can we talk about Epilepsy in…
August 22, 2022

Read more

PharmaShots Interview Mahesh Karande, CEO of Omega Therapeutics Shares Insights from the Preclinical Data Presented at the AACR 2022
VIEWPOINTS

PharmaShots Interview: Mahesh Karande, CEO of Omega Therapeutics Shares Insights from the Preclinical Data Presented at the AACR 2022

Shots:Mahesh talked about the data presented on its lead candidate in hepatocellular carcinoma at the AACR 2022Mahesh also spoke about Omega’s drug-development platform that identifies and targets specific and unique DNA sequences of regulatory elements The interview gives a profound grip on Omega’s development strategies to use mRNA therapeutics as a new class…
July 19, 2022

Read more

Viewpoints_Lloyd Miller
VIEWPOINTS

PharmaShots Interview: Janssen’s Lloyd Miller Shares Insight on the Data of Tremfya (guselkumab) Presented at EADV 2021

In an interview with PharmaShots, Lloyd Miller, MD, Ph.D., Vice President, Immunodermatology Disease Area Leader at Janssen shares his views on the data presented at EADV 2021 about patients who switch to Tremfya (guselkumab) from Humira (adalimumab) in P-III VOYAGE 1 & 2 trials for PsO & also highlighting the P-III DISCOVER-1 & 2 trial for PsAShots:The P-III VOYAGE 1 &…
November 10, 2021

Read more

Viewpoints_Dr. Bob Cobuzzi
VIEWPOINTS

PharmaShots Interview: Diffusion’s Dr. Bob Cobuzzi Shares Insights on the Trans Sodium Crocetinate (TSC) to Improve Hypoxia

In an interview with PharmaShots, Dr. Bob Cobuzzi, CEO, President, and Board Member at Diffusion shared his views on the trans sodium crocetinate (TSC) to improve patient outcomes & paradigm of oxygen deprivation treatmentShots:Diffusion's TSC directly targets and relieves oxygen-deprivation in affected tissue by enhancing oxygen diffusion & was designed to treat hypoxia include trauma, heart attack, stroke,…
November 3, 2021

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]